Article Sidebar
Main Article Content
First-line Eradication of Helicobacter pylori Infection with High-Dose Amoxicillin and Vonoprazan: A Systematic Review and Meta-analysis
Main Article Content
Abstract
Background/Aims: Due to increasing Helicobacter pylori resistance, the effectiveness of proton pump inhibitor-based regimens has
diminished. There is a need to assess the high-dose amoxicillin (≥3 g/day) and vonoprazan dual therapy through meta-analysis to determine if it is more effective than previous protocols.
Materials and Methods: A computer search of PubMed, Web of Science, Cochrane Library, Embase, and ClinicalTrials.gov was carried out to identify randomized controlled trials of massive dose amoxicillin and vonoprazan double treatment for H. pylori infection, up to June 2023. The primary outcome measures were the eradication rate and adverse event rate.
Results: A total of 7 studies encompassing 2601 patients were analyzed. The eradication rate of the high-dose dual group has no statistically significant differences compared to the control group (non-high-dose amoxicillin combined with vonoprazan) in intention-totreat (ITT) [OR=1.12, 95% CI (0.85, 1.48), P = .42] and per-protocol (PP) analysis [OR=1.08, 95% CI (0.74, 1.58), P = .69]. The incidence of adverse events [OR=0.63, 95% CI (0.45, 0.88), P = .007] was significantly reduced in the dual treatment group. Subgroup analysis revealed that the eradication rate in China [OR=1.34, 95% CI (1.01, 1.87), P = .04] was higher for the high-dose dual group compared with the control group in ITT analysis.
Conclusion: The eradication rate of high-dose amoxicillin and vonoprazan dual regimen is similar to that of previous regimens, and the
adverse event rate is significantly lower.
Cite this article as: Yu H, Zhou Z, Liu Z. First-line eradication of helicobacter pylori infection with high-dose amoxicillin and
vonoprazan: A systematic review and meta-analysis. Turk J Gastroenterol. 2025;36(7):410-419.
Article Details
References
1. Scott D, Weeks D, Melchers K, Sachs G. The life and death of
Helicobacter pylori. Gut. 1998;43 Suppl 1(Suppl 1):S56-S60.
[CrossRef]
2.Crowe SE. Helicobacter pylori infection. N Engl J Med.
2019;380(12):1158-1165. [CrossRef]
3.Ulasoglu C, Temiz HE, Sağlam ZA. The relation of cytotoxin-associated gene-A seropositivity with vitamin B12 deficiency in Helicobacter pylori-positive patients. BioMed Res Int. 2019;2019:1450536.
[CrossRef]
4.Sapmaz F, Başyiğit S, Kalkan İH, Kısa Ü, Kavak EE, Güliter S. The
impact of Helicobacter pylori eradication on serum hepcidin-25 level
and iron parameters in patients with iron deficiency anemia. Wien
Klin Wochenschr. 2016;128(9-10):335-340. [CrossRef]
5.Sugano K, Tack J, Kuipers EJ, et al. Kyoto Global Consensus Report
on Helicobacter pylori gastritis. Gut. 2015;64(9):1353-1367.
[CrossRef]
6.Malfertheiner P, Megraud F, Rokkas T, et al. Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus
report. Gut. 2022;71:gutjnl-2022-327745. [CrossRef]
7.Katelaris P, Hunt R, Bazzoli F, et al. Helicobacter pylori World Gastroenterology Organization global guideline. J Clin Gastroenterol.
2023;57(2):111-126. [CrossRef]
8.Kasahun GG, Demoz GT, Desta DM. Primary resistance pattern of
Helicobacter pylori to antibiotics in adult population: a systematic
review. Infect Drug Resist. 2020;13:1567-1573. [CrossRef]
9.Sugimoto M, Furuta T, Shirai N, et al. Evidence that the degree and
duration of acid suppression are related to Helicobacter pylori eradication by triple therapy. Helicobacter. 2007;12(4):317-323.
[CrossRef]
10. Clyne M, Labigne A, Drumm B. Helicobacter pylori requires an
acidic environment to survive in the presence of urea. Infect Immun.
1995;63(5):1669-1673. [CrossRef]
11. Strand DS, Kim D, Peura DA. 25 years of proton pump inhibitors:
a comprehensive review. Gut Liver. 2017;11(1):27-37. [CrossRef]
12. Inatomi N, Matsukawa J, Sakurai Y, Otake K. Potassium-competitive acid blockers: advanced therapeutic option for acid-related
diseases. Pharmacol Ther. 2016;168:12-22. [CrossRef]
13. Veettil SK, Sadoyu S, Bald EM, et al. Association of proton-pump
inhibitor use with adverse health outcomes: a systematic umbrella
review of meta-analyses of cohort studies and randomised controlled trials. Br J Clin Pharmacol. 2022;88(4):1551-1566. [CrossRef]
14. Scarpignato C, Gatta L, Zullo A, Blandizzi C, SIF-AIGO-FIMMG
Group, Italian Society of Pharmacology, the Italian Association of
Hospital Gastroenterologists, and the Italian Federation of General
Practitioners. Effective and safe proton pump inhibitor therapy in
acid-related diseases - A position paper addressing benefits and
potential harms of acid suppression. BMC Med. 2016;14(1):179.
[CrossRef]
15. Garnock-Jones KP. Vonoprazan: first global approval. Drugs.
2015;75(4):439-443. [CrossRef]
16. Laine L, Sharma P, Mulford DJ, et al. Pharmacodynamics and
pharmacokinetics of the potassium-competitive acid blocker vonoprazan and the proton pump inhibitor lansoprazole in US subjects.
Am J Gastroenterol. 2022;117(7):1158-1161. [CrossRef]17. Huang J, Lin Y. Vonoprazan on the eradication of Helicobacter
pylori infection. Turk J Gastroenterol. 2023;34(3):221-226.
[CrossRef]
18. Jenkins H, Sakurai Y, Nishimura A, et al. Randomised clinical trial:
safety, tolerability, pharmacokinetics and pharmacodynamics of
repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects. Aliment Pharmacol
Ther. 2015;41(7):636-648. [CrossRef]
19. Suzuki S, Gotoda T, Kusano C, et al. Seven-day vonoprazan and
low-dose amoxicillin dual therapy as first-line Helicobacter pylori
treatment: a multicentre randomised trial in Japan. Gut.
2020;69(6):1019-1026. [CrossRef]
20.Graham DY, Lu H, Yamaoka Y. A report card to grade Helicobacter pylori therapy. Helicobacter. 2007;12(4):275-278. [CrossRef]
21. Bi H, Chen X, Chen Y, et al. Efficacy and safety of high-dose
esomeprazole-amoxicillin dual therapy for Helicobacter pylori rescue
treatment: a multicenter, prospective, randomized, controlled trial.
Chin Med J (Engl). 2022;135(14):1707-1715. [CrossRef]
22.Helicobacter pylori study group, Chinese society of gastroenterology. Chinese Medical Association. Chinese National Clinical Practice Guideline on Helicobacter pylori Eradication Treatment. Chin J
Digest. 2022;42:745-756.
23.Qian HS, Li WJ, Dang YN, et al. Ten-day vonoprazan-amoxicillin
dual therapy as a first-line treatment of Helicobacter pylori infection
compared with bismuth-containing quadruple therapy. Am J Gastroenterol. 2023;118(4):627-634. [CrossRef]
24.Chey WD, Mégraud F, Laine L, López LJ, Hunt BJ, Howden CW.
Vonoprazan triple and dual therapy for Helicobacter pylori infection
in the United States and Europe: randomized clinical trial. Gastroenterology. 2022;163(3):608-619. [CrossRef]
25.Hu Y, Xu X, Ouyang Y-B, et al. Optimization of vonoprazanamoxicillin dual therapy for eradicating Helicobacter pylori infection
in China: a prospective, randomized clinical pilot study. Helicobacter.
2022;27(4):e12896. [CrossRef]
26.Lin Y, Xu H, Yun J, Yu X, Shi Y, Zhang D. The efficacy of vonoprazan combined with different dose amoxicillin on eradication of
Helicobacter pylori: an open, multicenter, randomized clinical study.
Ann Transl Med. 2022;10(18):987. [CrossRef]
27. Hu J, Mei H, Su NY, et al. Eradication rates of Helicobacter pylori
in treatment-naive patients following 14-day vonoprazan-amoxicillin dual therapy: a multicenter randomized controlled trial in China.
Helicobacter. 2023;28(4):e12970. [CrossRef]
28.Peng X, Chen H-W, Wan Y, et al. Combination of vonoprazan and
amoxicillin as the first-line Helicobacter pylori eradication therapy:
a multicenter, prospective, randomized, parallel-controlled study.
Clin Exp Med. 2023;23(7):4011-4019. [CrossRef]
29.Hu Y, Xu X, Liu XS, et al. Fourteen-day vonoprazan and low- or
high-dose amoxicillin dual therapy for eradicating Helicobacter
pylori infection: a prospective, open-labeled, randomized non-inferiority clinical study. Front Immunol. 2022;13:1049908. [CrossRef]
30.Warren JR, Marshall B. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet. 1983;1(8336):1273-1275.
31. Gong Y, Yuan Y. Resistance mechanisms of Helicobacter pylori
and its dual target precise therapy. Crit Rev Microbiol. 2018;44(3):371-
392. [CrossRef]
32.Shin JM, Inatomi N, Munson K, et al. Characterization of a novel
potassium-competitive acid blocker of the gastric H, K-ATPase,
1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-Nmethylmethanamine monofumarate (TAK-438). J Pharmacol Exp
Ther. 2011;339(2):412-420. [CrossRef]
33.Arikawa Y, Nishida H, Kurasawa O, et al. Discovery of a novel
pyrrole derivative 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-
1H-pyrrol-3-yl]-N-methylmethanamine fumarate (TAK-438) as a
potassium-competitive acid blocker (P-CAB). J Med Chem.
2012;55(9):4446-4456. [CrossRef]
34.ScottDR, MunsonKB, Marcus EA, Lambrecht NW, Sachs G. The binding selectivity of vonoprazan (TAK-438) to the gastric H+, K+ -ATPase.
Aliment Pharmacol Ther. 2015;42(11-12):1315-1326. [CrossRef]
35.Horii T, Suzuki S, Takano C, et al. Lower impact of vonoprazanamoxicillin dual therapy on gut microbiota for Helicobacter pylori
eradication. J Gastroenterol Hepatol. 2021;36(12):3314-3321.
[CrossRef]
36.Hooi JKY, Lai WY, Ng WK, et al. Global prevalence of Helicobacter
pylori infection: systematic review and meta-analysis. Gastroenterology. 2017;153(2):420-429. [CrossRef]
37. Mégraud F, Graham DY, Howden CW, et al. Rates of antimicrobial
resistance in Helicobacter pylori isolates from clinical trial patients
across the US and Europe. Am J Gastroenterol. 2023;118(2):269-275.
[CrossRef]
38.Echizen H. The first-in-class potassium-competitive acid blocker,
vonoprazan fumarate: pharmacokinetic and pharmacodynamic
considerations. Clin Pharmacokinet. 2016;55(4):409-418. [CrossRef]
39.Sugimoto M, Hira D, Murata M, Kawai T, Terada T. Effect of antibiotic susceptibility and cyp3a4/5 and cyp2c19 genotype on the
outcome of vonoprazan-containing Helicobacter pylori eradication
therapy. Antibiotics (Basel). 2020;9(10):645. [CrossRef]